Sensitivity of doxorubicin-resistant cells to sorafenib: Possible role for inhibition of eukaryotic initiation factor-2α phosphorylation

International Journal of Oncology

Volumn 37, Issue 2, 2010, Pages 509-517

  Shiota, Masaki ^a   Eto, Masatoshi ^b   Yokomizo, Akira ^a   Tada, Yasuhiro ^a   Takeuchi, Ario ^a   Itsumi, Momoe ^a   Tatsugami, Katsunori ^a   Uchiumi, Takeshi ^a   Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Doxorubicin; eIF2 ; PERK; Sorafenib; Urothelial cancer

Indexed keywords

DOXORUBICIN; HYDROGEN PEROXIDE; INITIATION FACTOR 2ALPHA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN KINASE R; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; INITIATION FACTOR 2; PERK KINASE; PYRIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; URINARY TRACT CARCINOMA; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; METABOLISM; NEOPLASM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL CULTURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EIF-2 KINASE; EUKARYOTIC INITIATION FACTOR-2; HUMANS; HYDROGEN PEROXIDE; NEOPLASMS; PHOSPHORYLATION; PYRIDINES; TUMOR CELLS, CULTURED;

EID: 77954149972     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-0000700     Document Type: Article

References (42)

1. Kotoh S, Naito S, Yokomizo A, et al: Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells. Cancer Res 54: 3248-3252, 1994. (Pubitemid 24208937)
2. Kotoh S, Naito S, Yokomizo A, Kohno K, Kuwano M and Kumazawa J: Enhanced expression of gamma-glutamylcysteine synthetase and glutathione S-transferase genes in cisplatin-resistant bladder cancer cells with multidrug resistance phenotype. J Urol 157: 1054-1058, 1997. (Pubitemid 27066316)
3. Yokomizo A, Ono M, Nanri H, et al: Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res 55: 4293-4296, 1995.
4. Hasegawa S, Abe T, Naito S, et al: Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br J Cancer 71: 907-913, 1995.
5. Tada Y, Wada M, Kuroiwa K, et al: MDR1 gene over-expression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin Cancer Res 6: 4618-4627, 2000. (Pubitemid 32110396)
6. Tada Y, Wada M, Migita T, et al: Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin. Int J Cancer 98: 630-635, 2002.
7. Tsunoda T, Koga H, Yokomizo A, et al: Inositol 1,4,5-trisphosphate (IP3) receptor type1 (IP3R1) modulates the acquisition of cisplatin resistance in bladder cancer cell lines. Oncogene 24: 1396-1402, 2005.
8. Yasui K, Mihara S, Zhao C, et al: Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res 64: 1403-1410, 2004.
9. Miyamoto N, Izumi H, Noguchi T, et al: Tip60 is regulated by circadian transcription factor clock and is involved in cisplatin resistance. J Biol Chem 283: 18218-18226, 2008.
10. Shiota M, Izumi H, Onitsuka T, et al: Twist promotes tumor cell growth through YB-1 expression. Cancer Res 68: 98-105, 2008.
11. Shiota M, Izumi H, Tanimoto A, et al: Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. Cancer Res 69: 3148-3156, 2009.
12. Naito S, Yokomizo A and Koga H: Mechanisms of drug resistance in chemotherapy for urogenital carcinoma. Int J Urol 6: 427-439, 1999.
13. Naito S, Koga H, Yokomizo A, et al: Molecular analysis of mechanisms regulating drug sensitivity and the development of new chemotherapy strategies for genitourinary carcinomas. World J Surg 24: 1183-1186, 2000.
14. Wilhelm S and Chien DS: BAY 43-9006: preclinical data. Curr Pharm Des 8: 2255-2257, 2002.
15. Lyons JF, Wilhelm S, Hibner B and Bollag G: Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 8: 219-225, 2001.
16. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109, 2004.
17. Eto M and Naito S: Molecular targeting therapy for renal cell carcinoma. Int J Clin Oncol 11: 209-213, 2006. (Pubitemid 44087119)
18. Abou-Alfa GK, Schwartz L, Ricci S, et al: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293-4300, 2006.
19. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134, 2007.
20. Akaza H, Tsukamoto T, Murai M, Nakajima K and Naito S: Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 37: 755-762, 2007.
21. Dever TE: Gene-specific regulation by general translation factors. Cell 108: 545-556, 2002.
22. Holcik M and Sonenberg N: Translational control in stress and apoptosis. Nat Rev Mol Cell Biol 6: 318-327, 2005.
23. Wek RC, Jiang HY and Anthony TG: Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans 34: 7-11, 2006.
24. Ron D and Walter P: Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8: 519-529, 2007.
25. Marciniak SJ and Ron D: Endoplasmic reticulum stress signaling in disease. Physiol Rev 86: 1133-1149, 2006. (Pubitemid 44521649)
26. Schröder M and Kaufman RJ: The mammalian unfolded protein response. Annu Rev Biochem 74: 739-789, 2005.
27. Harding HP, Zhang Y, Zeng H, et al: An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 11: 619-633, 2003.
28. Vattem KM and Wek RC: Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. Proc Natl Acad Sci USA 101: 11269-11274, 2004.
29. Lu PD, Harding HP and Ron D: Translation reinitiation at alternative open reading frames regulates gene expression in an integrated stress response. J Cell Biol 167: 27-33, 2004.
30. Shiota M, Izumi H, Onitsuka T, et al: Twist and p53 reciprocally regulate target genes via direct interaction. Oncogene 27: 5543-5553, 2008.
31. Shiota M, Yokomizo A, Tada Y, et al: Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene 29: 237-250, 2010.
32. Shiota M, Eto M, Yokomizo A, et al: Sorafenib with doxorubicin augments cytotoxicity to renal cell cancer through PERK inhibition. Int J Oncol 36: 1521-1531, 2010.
33. Benchekroun MN, Catroux P, Montaudon D and Robert J: Development of mechanisms of protection against oxidative stress in doxorubicin-resistant rat tumoral cells in culture. Free Radic Res Commun 11: 137-144, 1990.
34. Reinhardt HC and Yaffe MB: Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol 21: 245-255, 2009.
35. McManus KJ and Hendzel MJ: The relationship between histone H3 phosphorylation and acetylation throughout the mammalian cell cycle. Biochem Cell Biol 84: 640-657, 2006. (Pubitemid 44703665)
36. Archambault V and Glover DM: Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 10: 265-275, 2009.
37. Vader G and Lens SM: The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 1786: 60-72, 2008.
38. Nitiss JL: DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer 9: 327-337, 2009.
39. Shi Y, An J, Liang J, et al: Characterization of a mutant pancreatic eIF-2alpha kinase, PEK, and co-localization with somatostatin in islet delta cells. J Biol Chem 274: 5723-5730, 1999.
40. Kane RC, Farrell AT, Saber H, et al: Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12: 7271-7278, 2006.
41. Richly H, Schultheis B, Adamietz IA, et al: Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. Eur J Cancer 45: 579-587, 2009.
42. Hauschild A, Agarwala SS, Trefzer U, et al: Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 27: 2823-2830, 2009.